Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. - Wikidata - wikimedia - TriplyDB

Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.

Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.

http://www.wikidata.org/entity/Q45730216

about

Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients Emerging treatment options for nasopharyngeal carcinoma Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy.Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma?Current management strategy of nasopharyngeal carcinoma.Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies Human papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic Southern Chinese patients Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population.Commutability of the Epstein-Barr virus WHO international standard across two quantitative PCR methods.Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma.Epstein-Barr Virus_Encoded LMP1 upregulates microRNA-21 to promote the resistance of nasopharyngeal carcinoma cells to cisplatin-induced Apoptosis by suppressing PDCD4 and Fas-L.Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma Posttransplant lymphoproliferative disease: pathogenesis, monitoring, and therapy.Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.Pretreatment Serum Lactate Dehydrogenase and N Classification Predict Long-Term Survival and Distant Metastasis in Patients With Nasopharyngeal Carcinoma Who Have A Positive Family History of Cancer.Positivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma.Frequency of Epstein Barr Virus Type 1 Among Nasopharyngeal Carcinomas in Iranian Patients Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma Current and emerging treatment options for nasopharyngeal carcinoma.The role of human papillomavirus in squamous carcinoma of the head and neck.Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers.Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy.Fluorodeoxyglucose-positron emission tomography in carcinoma nasopharynx: Can we predict outcomes and tailor therapy based on postradiotherapy fluorodeoxyglucose-positron emission tomography?An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma.

P2860

Q26823898-CF28B946-3697-4C6D-9A13-BFEB04A32879 Q26995560-289B744B-36DB-4873-9DC9-ECF3C64A8455 Q33218405-4BBAF692-4653-42C2-AB6F-8EFEB7BBEB95 Q33262273-E8D8D7E1-14B3-4268-BED1-72330B5BEB3C Q33685029-AD136D4D-1F2A-4C60-8578-43DFF159789D Q33702316-420CAF86-6AD3-4104-A6E1-E5A7245A53FB Q33764579-4DC7A0B1-7D38-4BD2-8A0D-119C3E60C183 Q33836183-12032718-1063-45F6-A702-05D05370698E Q33901342-5F458CCF-1CC5-4952-9A43-87F00AD5C71D Q34121782-9DED5E46-23EC-469E-9357-036EE20966E0 Q34286259-D35DE934-BAA4-47EE-BB71-D04A99EA2606 Q34298224-1DC5D79B-7204-4259-8C90-FBEB1AC5C708 Q34565533-817A74CC-1F84-47B5-9315-CCE889412FC2 Q35032548-61AA87A2-07DE-45BA-9EA6-92E611678870 Q35087399-8401DCE6-0FB0-4E77-8D53-D0910664AD46 Q35190684-481C87EB-E474-4327-875E-4FE53ADF72AE Q35391282-932AAD0C-D94C-429A-8589-C0EC3DAD997A Q35507358-11FBA5D1-77AF-48EE-A48B-9548B41FED48 Q35619542-5C2612DF-7DAE-4F37-924B-7EC9557A021F Q35670356-6CAD387C-A01C-4243-B302-CF3D1F9B4C7A Q35678382-321E019A-DC03-418D-9D3F-268081BF385A Q35769567-2BD1E7C3-6FED-4B9B-B711-97A8C70F1284 Q36076485-7FACBF46-5111-448D-9137-92BDEA0F2ED3 Q36117881-B1E45EDF-CE73-4E8B-9BE5-CBEF2188D077 Q36152889-3E3761A6-4B83-4D0F-AF06-23B1861CCBAB Q36189973-BE099DDC-7308-4EE4-8910-D0B60DE514ED Q36256111-24207013-E90C-46F2-AD71-06C8006760F4 Q36305182-3D9B00AD-8E61-43AB-8315-4BD58872E089 Q36323473-1FD081CB-EB0C-4222-8554-52C94985FA6E Q36335515-0E35DBE0-E1C8-4F27-8EB6-95F1E17B4799 Q36359374-026278BD-A6F8-46C7-92C3-5799C993E19D Q36409233-E2B88D05-7ABF-415A-B654-CB2F5AE85DB7 Q36546040-5C25DC89-FC0A-416E-B3FB-76CAD83C2660 Q36566873-626FAA58-233D-42B2-B14C-A34C81ABD771 Q36610034-EB34D040-C436-4B6B-917F-2B8AA7562FF8 Q36616746-3E4A003D-4044-42A1-9B90-A6AD142AAD9C Q36628563-84BF1CD1-68C9-49F2-84C4-5D742300084A Q36629614-1C38BF28-AE19-412B-BE75-8A442999F5C6 Q36696385-9B90E5FD-D61E-4A24-B008-C5F2F37678FE Q36778016-5AA66CEF-558E-497B-AEA2-9A16169AAB77

P2860

Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.

http://www.wikidata.org/entity/Q45730216

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.

@en

Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.

@nl

type

label

Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.

@en

Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.

@nl

prefLabel

Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.

@en

Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.

@nl

P1433

Q45730216-06A019A7-FD9F-49A8-B2EB-92A136AC0DDF

P1476

Q45730216-CE427FB5-DD22-43D7-828F-135D63CDD99F

P2093

Q45730216-12F296F8-7ED2-45B6-BCA2-1E51AAC9E308

Q45730216-27AB78C7-08E4-44BA-95EF-AFED59056741

Q45730216-5C5E6EA2-DF93-4C7D-9465-E6D4BF47EBE4

Q45730216-6BD15398-3A5C-4DD3-BEAD-7FF550407536

Q45730216-788C9A02-53C9-401F-BB11-B64CF093FF77

Q45730216-882C712E-1E85-44DD-BBC8-3614B9BDB6B1

Q45730216-991431A4-4807-4113-BA0E-51D0649970E9

Q45730216-A7F915C5-2C7D-46F0-97A8-0BE3CCF69B60

Q45730216-B8146541-4F68-4DC9-8A3F-FF937301FE90

Q45730216-E0EABE96-1996-49F2-BF35-46906738B326

P304

Q45730216-688A971C-CC74-40A6-85FA-E910A9D9AFB1

P31

Q45730216-045B550D-B577-4359-919A-FD3549871018

P356

Q45730216-5DB9CBDB-1E90-4980-B237-164FA9A1F013

P407

Q45730216-05C1EA29-D7CB-4278-9CDD-B1C23C87CAC6

P433

Q45730216-E2E6526C-FE3E-4E06-8869-14E6B292E6B5

P478

Q45730216-33DF13D7-416E-470C-8334-EA5F28DAD1CC

P50

Q45730216-212C9F0B-BBC2-4DB9-A0A3-4F3F0AA671F0

P577

Q45730216-24C47668-902B-4D21-97DE-E0B5404D636E

P5875

Q45730216-A8D24BBB-181E-4781-8EDC-9135F9E36A62

P698

Q45730216-690E86FD-0241-4485-9A52-FC2C82C82843

P921

Q45730216-4981DA8B-3161-4453-9753-6557E148D724

Q45730216-9CAA04E7-12F8-4FBB-ABFA-EFD67110C09C

P356

P1433

Journal of the National Cancer Institute

P1476

Plasma Epstein-Barr virus DNA ...... ated nasopharyngeal carcinoma.

@en

P2093

Anthony T C Chan

http://www.w3.org/2001/XMLSchema#string

Brigette B Y Ma

http://www.w3.org/2001/XMLSchema#string

Dolly P Huang

http://www.w3.org/2001/XMLSchema#string

Frankie Mo

http://www.w3.org/2001/XMLSchema#string

Lisa Y S Chan

http://www.w3.org/2001/XMLSchema#string

Maria Lai

http://www.w3.org/2001/XMLSchema#string

Philip J Johnson

http://www.w3.org/2001/XMLSchema#string

Sing-Fai Leung

http://www.w3.org/2001/XMLSchema#string

Stephen Ho

http://www.w3.org/2001/XMLSchema#string

Y M Dennis Lo

http://www.w3.org/2001/XMLSchema#string

P304

1614-1619

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/94.21.1614

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

Benny Chung-Ying Zee

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11045842

http://www.w3.org/2001/XMLSchema#string

P698

12419787

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

Epstein–Barr virus